JMI Syringes & Medical Devices Limited (DSE:JMISMDL)
Bangladesh
· Delayed Price · Currency is BDT 152.50
+13.80 (9.95%)
At close: Apr 9, 2025
DSE:JMISMDL Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Revenue | 1,907 | 1,794 | 1,755 | 2,438 | 1,994 | 1,977 | Upgrade
|
| Revenue Growth (YoY) | 9.22% | 2.19% | -28.01% | 22.31% | 0.86% | 11.13% | Upgrade
|
| Cost of Revenue | 1,541 | 1,504 | 1,534 | 2,049 | 1,657 | 1,590 | Upgrade
|
| Gross Profit | 366.43 | 289.79 | 221.49 | 389.31 | 336.76 | 386.99 | Upgrade
|
| Selling, General & Admin | 168.83 | 155.77 | 141.69 | 176.37 | 150.89 | 158.44 | Upgrade
|
| Other Operating Expenses | 0.42 | 0.11 | 7.96 | - | - | 0 | Upgrade
|
| Operating Expenses | 169.85 | 156.49 | 150.24 | 176.97 | 151.29 | 180.05 | Upgrade
|
| Operating Income | 196.58 | 133.3 | 71.24 | 212.34 | 185.46 | 206.95 | Upgrade
|
| Interest Expense | -1.08 | -2.52 | -12.93 | -13.18 | -11.18 | -4.95 | Upgrade
|
| Interest & Investment Income | 0.53 | 0.27 | 1.42 | 6.89 | 10.4 | 12.41 | Upgrade
|
| Currency Exchange Gain (Loss) | -7.48 | -5.31 | - | -0.18 | 0.77 | 0.72 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.27 | 5.33 | 4.73 | 1.79 | 0.71 | 0.8 | Upgrade
|
| EBT Excluding Unusual Items | 193.81 | 131.07 | 64.46 | 207.67 | 186.17 | 215.93 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.05 | - | - | Upgrade
|
| Pretax Income | 193.81 | 131.07 | 64.46 | 207.72 | 186.17 | 215.93 | Upgrade
|
| Income Tax Expense | 108.01 | 92.19 | 214.43 | 107.12 | 97.06 | 119.89 | Upgrade
|
| Net Income | 85.8 | 38.88 | -149.96 | 100.6 | 89.11 | 96.04 | Upgrade
|
| Net Income to Common | 85.8 | 38.88 | -149.96 | 100.6 | 89.11 | 96.04 | Upgrade
|
| Net Income Growth | - | - | - | 12.89% | -7.22% | 44.30% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| EPS (Basic) | 2.85 | 1.29 | -4.99 | 3.35 | 2.96 | 3.20 | Upgrade
|
| EPS (Diluted) | 2.85 | 1.29 | -4.99 | 3.35 | 2.96 | 3.20 | Upgrade
|
| EPS Growth | - | - | - | 12.89% | -7.22% | 44.30% | Upgrade
|
| Free Cash Flow | 125.5 | 109.3 | 21.29 | -57.08 | 124.8 | -279.9 | Upgrade
|
| Free Cash Flow Per Share | 4.18 | 3.64 | 0.71 | -1.90 | 4.15 | -9.31 | Upgrade
|
| Dividend Per Share | 1.000 | 1.000 | 1.000 | 3.600 | 2.206 | 2.206 | Upgrade
|
| Dividend Growth | - | - | -72.22% | 63.20% | - | - | Upgrade
|
| Gross Margin | 19.21% | 16.16% | 12.62% | 15.97% | 16.89% | 19.58% | Upgrade
|
| Operating Margin | 10.31% | 7.43% | 4.06% | 8.71% | 9.30% | 10.47% | Upgrade
|
| Profit Margin | 4.50% | 2.17% | -8.54% | 4.13% | 4.47% | 4.86% | Upgrade
|
| Free Cash Flow Margin | 6.58% | 6.09% | 1.21% | -2.34% | 6.26% | -14.16% | Upgrade
|
| EBITDA | 264.19 | 204.06 | 145.51 | 285.59 | 256.73 | 271.5 | Upgrade
|
| EBITDA Margin | 13.85% | 11.38% | 8.29% | 11.71% | 12.88% | 13.74% | Upgrade
|
| D&A For EBITDA | 67.62 | 70.75 | 74.27 | 73.24 | 71.27 | 64.55 | Upgrade
|
| EBIT | 196.58 | 133.3 | 71.24 | 212.34 | 185.46 | 206.95 | Upgrade
|
| EBIT Margin | 10.31% | 7.43% | 4.06% | 8.71% | 9.30% | 10.47% | Upgrade
|
| Effective Tax Rate | 55.73% | 70.34% | 332.63% | 51.57% | 52.14% | 55.52% | Upgrade
|
| Advertising Expenses | - | 8.98 | 9.1 | 12.47 | 6.04 | 0.41 | Upgrade
|
Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.